Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous leukemia, or metastatic breast cancer

Hum Gene Ther. 1993 Apr;4(2):205-22. doi: 10.1089/hum.1993.4.2-205.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow / pathology
  • Bone Marrow Transplantation*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Cisplatin / administration & dosage
  • Clinical Protocols
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Etoposide / administration & dosage
  • Feasibility Studies
  • Genetic Therapy*
  • Genetic Vectors
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Ifosfamide / administration & dosage
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Melphalan / administration & dosage
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / therapy*
  • Neoplasm Metastasis
  • Retroviridae / genetics
  • Transfection
  • Transplantation, Autologous
  • Whole-Body Irradiation

Substances

  • Etoposide
  • Cyclophosphamide
  • Cisplatin
  • Melphalan
  • Ifosfamide

Supplementary concepts

  • ICE protocol 1